UNSPSC 51414101: Regadenoson

This classification denotes a vasodilating agent with the molecular formula C15H18N8O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2XLN4Y044H, chemically known as adenosine, 2-(4-((methylamino)carbonyl)-1h-pyrazol-1-yl)- but generally known as regadenoson, which bears US NIH Compound Identifier 219024. European Medicines Agency schedules Regadenoson in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30494.

UNSPSC 51414101 Regadenoson is a Commodity code that covers specific pharmaceutical products and their procurement by state and local health and emergency services agencies. State and local governments procure regadenoson and related advanced life support medications through sealed-bid and cooperative purchasing frameworks to supply emergency medical services, fire rescue departments, and state pharmacy benefit programs. The issuing bodies include city purchasing departments (such as the City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Procurements specify strict requirements for expiration dating, Cold Chain management where applicable, FDA compliance, Safety Data Sheets, OSHA Hazard Communication Standards, and often mandate delivery within ten calendar days. Small Local Business Enterprise set-asides appear in city-level solicitations, with some jurisdictions offering bid discounts for certified SLBE participation and requiring accessibility documentation under WCAG 2.2 and Section 508 standards.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, seeking four specific medication line items including epinephrine, adenosine, labetalol, and diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a one-year term plus optional two-year renewals. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, soliciting vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026, response deadline, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon through three authorized wholesalers, with a two-year initial term and optional extensions.